RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I clinical trial is studying the side effects and best dose of RO4929097 when
given together with capecitabine in treating patients with refractory solid tumors. RO4929097
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving RO4929097 together with
chemotherapy may kill more tumor cells.